What we do
The EIF in 2020
Coronavirus: The EIB Group’s initiatives to address its economic consequences
Pan-European Guarantee Fund – EGF
Institutional investors
Equity products
AI Co-Investment Facility
Climate & Infrastructure Funds
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
ESCALAR Programme
Debt products
New ESIF ERDF Guarantee Fund initiative in Greece
EFSI Private Credit Programme
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
Skills & Education Guarantee Pilot
EREM debt products
Single EU Debt Financial Instrument
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
EaSI Funded Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Fons d’Inversió en Tecnologia Avançada (FITA) Catalonia
Dutch Future Fund (DFF)
Dutch Alternative Credit Instrument (DACI)
PORTUGAL BLUE: a new initiative for blue economy investments
JEREMIE Greece Reflows – Business Angels’ Co-Investment Equity Instrument
German Corona Matching Facility (CMF)
Portugal Growth programme
Croatian Growth Investment Programme (CROGIP)
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund 1 (BIF 1)
Baltic Innovation Fund 2 (BIF 2)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Competitiveness Fund-of-Funds for SMEs in Romania
The Cyprus Entrepreneurship Fund (CYPEF)
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
ESIF Fund-of-Funds Greece
EAFRD FoF Portugal
EAFRD FoF Romania
The ERP-EIF Facility
ERP-EIF Co-Investment Growth Facility
The LfA-EIF Facilities
The German Future Fund (GFF) - EIF Growth Facility
INAF – French National Agricultural Initiative
ESIF Energy Efficiency and Renewable Energy Malta
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
InvestBG Equity Instrument
Romania Recovery Equity Fund of Funds
JEREMIE Romania Reflows – Equity Instrument
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Portugal Venture Capital Initiative (PVCi)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)
EAFRD FoF Greece
Irish Innovation Seed Fund (IISF)

DNA Script: synthetic DNA on demand


DNA Script was created to revolutionize access to synthetic DNA. The technology that the company has developed allows for a rapid, convenient way to access DNA on demand through SYNTAX, the world’s first benchtop DNA printer powered by enzymatic technology.

“Getting access to synthetic DNA is a real challenge for any life-science project. Our aim is to provide a tool that will allow life-science teams to manufacture the synthetic DNA they need for their project on-site in a matter of a few hours rather than several days,” explains Thomas Ybert, co-founder and CEO of DNA Script.  “To synthesise DNA today, you need the infrastructure to work with dangerous chemicals. We conceptualised an alternative way of synthesising DNA using enzymes instead of chemicals. It’s faster, easier, safer and can be done on-site. Ultimately, the time saved will make a huge difference in terms of control measures, cases, casualties and economic impact.”

In the context of a pandemic, DNA synthesis will be key in the development of any vaccine… “Ultimately, we want to deploy our devices as broadly as possible, down to local hospitals,” says Thomas. “Imagine a new outbreak in a remote region, a new virus… With our instrument, they could quickly provide the DNA needed to sequence the first genome of the virus, and access critical information within hours. The same SYNTAX instrument will be able to iterate, very quickly, diagnostic tests, and then you can quickly test people, all within 24-48 hours. Without decentralised DNA synthesis devices, it could take days or even weeks to liaise with a centralised DNA production site. You can then confine potential infected people fast and stop a pandemic, without having to quarantine a whole continent. For the Covid-19 virus, it could still be useful to help monitor its evolution if it mutates. You need to update your knowledge, sequence the new virus mutants and update your tests, so we could play a role in that regard.”

In 2016, DNA Script received an important equity investment from Kurma Partners, a venture capital firm backed by the EIF, that helped the company on its path to professionalisation. “The seed financing helped us turn into a real company, make our first hires and move to the proof of concept stage. Initially we were just three early entrepreneurs, of which only one full-time.”

And the next step for DNA Script? “Well, we are just building our first beta prototype, and then we want to enter evaluation programmes, test the device around partners, get technical feedback and fine-tune it. When the machine is widely available, people will be asking themselves ‘how did we live without it’?”

Company: DNA Script (France)

Type of business: biotechnology

EIF financing: RCR mandate and own resources 

Financial intermediary: Kurma Partners 

For further information about EIF intermediaries in France, please refer to: http://www.eif.org/what_we_do/where/fr/index.htm


We use cookies to give the best browser experience on our website. or change cookie settings.

Note: Following the recent withdrawal of the United Kingdom from the European Union, we are updating the relevant EIF.org pages.


Copyright ©

 European Investment Fund   – The European Investment Fund is not responsible for the content of external internet sites.